Humanized antibody

兰洛珠单抗（INN：Landogrozumab；开发代号：LY2495655），或译兰度古珠单抗，是一种人源化（英语：Humanized antibody）单克隆抗体和实验药物，设计用于治疗肌肉萎缩性疾病。该药物由礼来公司开发。 Statement On A Nonproprietary Name Adopted

多玛洛珠单抗（INN：Domagrozumab；开发代号：PF-06252616）是一种人源化（英语：Humanized antibody）单克隆抗体，设计用于治疗杜氏肌营养不良症。这种药物是由辉瑞公司开发。辉瑞公司在2项人体试验结果令人失望后于2018年停止了开发。 Statement On A Nonproprietary

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced

(DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol. Dec 2007

Allende D, et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric